Cargando…
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115817/ https://www.ncbi.nlm.nih.gov/pubmed/27900206 http://dx.doi.org/10.1136/esmoopen-2016-000100 |
_version_ | 1782468576765018112 |
---|---|
author | Cherny, N I Sullivan, R Dafni, U Kerst, J M Sobrero, A Zielinski, C Piccart, M J Bogaerts, J Tabernero, J Latino, N J de Vries, E G E |
author_facet | Cherny, N I Sullivan, R Dafni, U Kerst, J M Sobrero, A Zielinski, C Piccart, M J Bogaerts, J Tabernero, J Latino, N J de Vries, E G E |
author_sort | Cherny, N I |
collection | PubMed |
description | The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies for reimbursement. From its inception the ESMO-MCBS Working Group has invited questions and critiques to promote understanding and to address misunderstandings regarding the nuanced use of the scale, and to identify shortcomings in the scale to be addressed in future planned revisions and updates. The ESMO-MCBS V.1.0 has attracted many questions regarding its development, structure and potential applications. These questions, together with responses from the ESMO-MCBS Working Group, have been edited and collated, and are herein presented as a supplementary resource. |
format | Online Article Text |
id | pubmed-5115817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51158172016-11-29 ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers Cherny, N I Sullivan, R Dafni, U Kerst, J M Sobrero, A Zielinski, C Piccart, M J Bogaerts, J Tabernero, J Latino, N J de Vries, E G E ESMO Open Review The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies for reimbursement. From its inception the ESMO-MCBS Working Group has invited questions and critiques to promote understanding and to address misunderstandings regarding the nuanced use of the scale, and to identify shortcomings in the scale to be addressed in future planned revisions and updates. The ESMO-MCBS V.1.0 has attracted many questions regarding its development, structure and potential applications. These questions, together with responses from the ESMO-MCBS Working Group, have been edited and collated, and are herein presented as a supplementary resource. BMJ Publishing Group 2016-10-18 /pmc/articles/PMC5115817/ /pubmed/27900206 http://dx.doi.org/10.1136/esmoopen-2016-000100 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Cherny, N I Sullivan, R Dafni, U Kerst, J M Sobrero, A Zielinski, C Piccart, M J Bogaerts, J Tabernero, J Latino, N J de Vries, E G E ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
title | ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
title_full | ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
title_fullStr | ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
title_full_unstemmed | ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
title_short | ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
title_sort | esmo - magnitude of clinical benefit scale v.1.0 questions and answers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115817/ https://www.ncbi.nlm.nih.gov/pubmed/27900206 http://dx.doi.org/10.1136/esmoopen-2016-000100 |
work_keys_str_mv | AT chernyni esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT sullivanr esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT dafniu esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT kerstjm esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT sobreroa esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT zielinskic esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT piccartmj esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT bogaertsj esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT taberneroj esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT latinonj esmomagnitudeofclinicalbenefitscalev10questionsandanswers AT devriesege esmomagnitudeofclinicalbenefitscalev10questionsandanswers |